1st Dec 2016 07:53
LONDON (Alliance News) - Clinigen Group PLC on Thursday said its breast cancer chemotherapy drug eribulin, which is trademarked as Halaven, is now registered by the Medicines Control Council in South Africa.
The treatment will be available in South Africa for women with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.
Eribulin was discovered and developed by Japanese pharmaceutical company Eisai and will be made available through a partnership with Clinigen's Link Healthcare division Equity Pharma.
"This is the first distribution agreement of this kind for Clinigen following our acquisition of Link Healthcare in 2015, and marks the continuation of a successful relationship with Eisai. As partners in the distribution of eribulin, we can leverage our comprehensive South African distribution network and local expertise to deliver this important medicine to eligible women across the country, marking an important moment in the fight against advanced breast cancer in the region," Chief Executive Shaun Chilton said in a statement.
By Karolina Kaminska; [email protected]; @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L